Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2023-05, Vol.25 (5), p.1413-1418
Main Authors: Koshino, Akihiko, Oshima, Megumi, Arnott, Clare, Fletcher, Robert A., Bakris, George L., Jardine, Meg, Mahaffey, Kenneth W., Perkovic, Vlado, Pollock, Carol, Heerspink, Hiddo J. L., Neuen, Brendon L.
Format: Article
Language:English
Subjects:
Antidiabetics
Canagliflozin - therapeutic use
cardiovascular disease
Cardiovascular Diseases
clinical trial
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetic nephropathy
Fatty liver
Fatty Liver - complications
Fatty Liver - drug therapy
fatty liver disease
Fibrosis
Humans
Kidney diseases
Renal Insufficiency, Chronic - complications
Renal Insufficiency, Chronic - drug therapy
Steatosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1462-8902
1463-1326
DOI:10.1111/dom.14978